Gesher Acquisition II
GSHR · NASDAQ
About GSHR
- Employees
- 0
- Headquarters
- Tel Aviv, Tel Aviv
- Listed
- Mar 21, 2025
- Sector
- N/A
- Industry
- N/A
GSHR key statistics
- Market cap
- 216.81M
- Price-earnings ratio
- 0.00
- Dividend yield
- —
- Average volume
- 18.58K
- Volume
- 107
- Open price
- $10.60
- High today
- $10.60
- Low today
- $10.60
- 52 Week high
- $10.61
- 52 Week low
- $10.19
Gesher Acquisition II (GSHR) at a glance
As of Oct 26, 2026, Gesher Acquisition II (GSHR) shares are priced at $10.60, giving the company a market cap of 216.81M and a price-to-earnings ratio of 0.00.
Volume so far is 107 shares, below the average of 18.58K shares a day.
Over the past year Gesher Acquisition II has ranged from $10.19 to $10.61, and now sits 98% of the way up that range.
Most active stocks
Highest trading volume today
- EARIEntertainment Arts Research$0.0002+0.00%
- RDARRaadr$0.0002+20.00%
- RCTRedCloud Holdings$0.0827+8.67%
- NUNu Holdings$12.59−16.95%
- EWZiShares MSCI Brazil ETF$34.15−19.82%
- MDEXMadison Technologies$0.0002−33.33%
- BBDBanco Bradesco S.A.$2.93−28.01%
- MASNMaison Luxe$0.0002+0.00%
- LTNCLabor Smart$0.0001+0.00%
- TGLTreasure Global$0.2427+9.57%
- AZTRAzitra$1.53
- ITUBItau Unibanco Holding S.A.$7.70−20.37%
Newly listed
Companies that went public in the past six weeks
- LYCALycia Therapeutics$28.85−3.83%
- DAVIDAVION HEALTHCARE$4.07−32.17%
- TCXBTCGX Acquisition Corp. II$10.27−2.10%
- CTYCITY THERAPEUTICS$20.79+0.10%
- IAMIambic Therapeutics$14.41+1.05%
- AMROAmaero$5.37−8.05%
- FLSCFrazier Life Sciences Acquisition Corp. II$10.28−0.19%
- TRXBTRex Bio$13.87+0.43%
- RTSNRetension Pharmaceuticals$14.24−6.62%
- PAXGUPine Tree Acquisition$10.02+0.15%
- PORTUSouthport Acquisition Corp. IIListed Oct 1, 2026
- CHWMChilwa Minerals$5.13+0.10%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.